Anocca

Anocca company information, Employees & Contact Information

Explore related pages

Related company profiles:

Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Sweden.

Company Details

Employees
120
Founded
-
Address
Forskargatan 20c, B229,sweden
Phone
46841080757
Email
in****@****cca.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
anocca.com
HQ
Södertälje
Looking for a particular Anocca employee's phone or email?

Anocca Questions

News

Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca - Nature

Memorable, distinctive, not too ‘sciencey’: why we named our biotech firm Anocca Nature

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer - Yahoo Finance

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer Yahoo Finance

Anocca steps into a KRAS battle | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Anocca steps into a KRAS battle | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Anocca Announces Authorisation of Clinical Trial - GlobeNewswire

Anocca Announces Authorisation of Clinical Trial GlobeNewswire

Anocca raises €38.4m to advance TCR-T leads vs. pancreatic cancer - European Biotechnology Magazine

Anocca raises €38.4m to advance TCR-T leads vs. pancreatic cancer European Biotechnology Magazine

Anocca's $46m boost for pancreatic cancer therapy - BioXconomy

Anocca's $46m boost for pancreatic cancer therapy BioXconomy

Anocca Raises Approx. USD46M in Funding - FinSMEs

Anocca Raises Approx. USD46M in Funding FinSMEs

Anocca announces authorisation pancreatic cancer trial - PharmaTimes

Anocca announces authorisation pancreatic cancer trial PharmaTimes

Anocca secures $46m to support pancreatic cancer therapy trials - Clinical Trials Arena

Anocca secures $46m to support pancreatic cancer therapy trials Clinical Trials Arena

Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer - Mynewsdesk

Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer Mynewsdesk

Swedish biotech gets $46M to run early TCR cell therapy clinical trial - Endpoints News

Swedish biotech gets $46M to run early TCR cell therapy clinical trial Endpoints News

Sweden’s Anocca secures $46 million for early-stage TCR-T therapy development - ArcticStartup - ArcticStartup

Sweden’s Anocca secures $46 million for early-stage TCR-T therapy development - ArcticStartup ArcticStartup

Shinobi and Anocca to advance cancer killing iPS-T cell therapies - BioProcess International

Shinobi and Anocca to advance cancer killing iPS-T cell therapies BioProcess International

Anocca AB and Shinobi Therapeutics to Develop Allogeneic TCR Engineered iPSC-derived T-Cell Therapies (TCR-iPS-T) for Solid Tumors - BioInformant

Anocca AB and Shinobi Therapeutics to Develop Allogeneic TCR Engineered iPSC-derived T-Cell Therapies (TCR-iPS-T) for Solid Tumors BioInformant

MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Anocca's TCR-T Pipeline - Stock Titan

MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Anocca's TCR-T Pipeline Stock Titan

Anocca raises SEK 400 million for large-scale development of cancer cell therapies - Yahoo Finance

Anocca raises SEK 400 million for large-scale development of cancer cell therapies Yahoo Finance

Anocca gains European authorisation for Phase I/II trial of pancreatic cancer drug - Clinical Trials Arena

Anocca gains European authorisation for Phase I/II trial of pancreatic cancer drug Clinical Trials Arena

Anocca submits application to EMA for pancreatic cancer trial - Clinical Trials Arena

Anocca submits application to EMA for pancreatic cancer trial Clinical Trials Arena

Anocca signs licensing deal for EmendoBio’s gene-editing tech - Pharmaceutical Technology

Anocca signs licensing deal for EmendoBio’s gene-editing tech Pharmaceutical Technology

Anocca raises $36.6M for large-scale development of cancer cell therapies - Labiotech.eu

Anocca raises $36.6M for large-scale development of cancer cell therapies Labiotech.eu

Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer - Mynewsdesk

Anocca Presents Data at ESMO Congress on Preclinical Development of its TCR-T Cell Therapies for Cancer Mynewsdesk

BRIEF—Anocca raises $36 million in equity financing - The Pharma Letter

BRIEF—Anocca raises $36 million in equity financing The Pharma Letter

Anocca & EmendoBio Team Up for Next-Gen Cell Therapy - Contract Pharma

Anocca & EmendoBio Team Up for Next-Gen Cell Therapy Contract Pharma

Sweden: Anocca raises SEK440m to advance clinical trial targeting pancreatic cancer - Investors in Healthcare

Sweden: Anocca raises SEK440m to advance clinical trial targeting pancreatic cancer Investors in Healthcare

Anocca Raises USD36.58M in Equity Funding - FinSMEs

Anocca Raises USD36.58M in Equity Funding FinSMEs

Sweden-based Anocca secures €25M from EIB to develop T-cell therapies for cancer - Silicon Canals

Sweden-based Anocca secures €25M from EIB to develop T-cell therapies for cancer Silicon Canals

Hans Stråberg: ”Kan komma att revolutionera cancerbehandling framöver” - Mynewsdesk

Hans Stråberg: ”Kan komma att revolutionera cancerbehandling framöver” Mynewsdesk

Top Anocca Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant